{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:47:58Z","timestamp":1788490078947,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1245\/s10434-025-18186-9","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T19:27:29Z","timestamp":1756409249000},"page":"10179-10192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Yuto","family":"Kamioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7384-3513","authenticated-orcid":false,"given":"Yukihiko","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seira","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Washimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Kanemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Rino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"3","key":"18186_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"9\u201310","key":"18186_CR2","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1080\/0284186X.2016.1197419","volume":"55","author":"J Ferlay","year":"2016","unstructured":"Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55(9\u201310):1158\u201360.","journal-title":"Acta Oncol"},{"issue":"11","key":"18186_CR3","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"1","key":"18186_CR4","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"10041","key":"18186_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). The Lancet. 2016;388(10041):248\u201357.","journal-title":"The Lancet"},{"issue":"25","key":"18186_CR6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med"},{"issue":"7","key":"18186_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/MPA.0b013e318258055c","volume":"41","author":"S Egawa","year":"2012","unstructured":"Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, et al. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012;41(7):985\u201392.","journal-title":"Pancreas"},{"issue":"11","key":"18186_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"8","key":"18186_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrd3926-c1","volume":"12","author":"H Jhoti","year":"2013","unstructured":"Jhoti H, Williams G, Rees DC, Murray CW. The \u2018rule of three\u2019 for fragment-based drug discovery: where are we now? Nat Rev Drug Discov. 2013;12(8):644\u20135.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"18186_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","volume":"15","author":"JP Neoptolemos","year":"2018","unstructured":"Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333\u201348.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"18186_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1053\/j.gastro.2004.12.036","volume":"128","author":"MG Bachem","year":"2005","unstructured":"Bachem MG, Sch\u00fcnemann M, Ramadani M, Siech M, Beger H, Buck A, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128(4):907\u201321.","journal-title":"Gastroenterology"},{"issue":"11","key":"18186_CR12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/nprot.2009.171","volume":"4","author":"MP Kim","year":"2009","unstructured":"Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4(11):1670\u201380.","journal-title":"Nat Protoc"},{"issue":"12","key":"18186_CR13","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1158\/1078-0432.CCR-16-1946","volume":"23","author":"C Pereira","year":"2017","unstructured":"Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, et al. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition. Clin Cancer Res. 2017;23(12):3203\u201313.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"18186_CR14","doi-asserted-by":"publisher","first-page":"i172","DOI":"10.1093\/bioinformatics\/bts236","volume":"28","author":"T Conway","year":"2012","unstructured":"Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED, et al. Xenome-a tool for classifying reads from xenograft samples. Bioinformatics. 2012;28(12):i172\u20138.","journal-title":"Bioinformatics"},{"issue":"11","key":"18186_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/nrc2735","volume":"9","author":"M Mancini","year":"2009","unstructured":"Mancini M, Toker A. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer. 2009;9(11):810\u201320.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"18186_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41419-019-2072-5","volume":"10","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, He R, Jiang Y, Liu D, Tao L, Yang M, et al. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Cell Death Dis. 2019;10(12):948.","journal-title":"Cell Death Dis"},{"issue":"17","key":"18186_CR17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605\u201317.","journal-title":"N Engl J Med"},{"issue":"4","key":"18186_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1159\/000315035","volume":"10","author":"A K\u00f6nig","year":"2010","unstructured":"K\u00f6nig A, Fernandez-Zapico ME, Ellenrieder V. Primers on molecular pathways\u2014the NFAT transcription pathway in pancreatic cancer. Pancreatology. 2010;10(4):416\u201322.","journal-title":"Pancreatology"},{"issue":"2","key":"18186_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1053\/j.gastro.2011.11.001","volume":"142","author":"S Baumgart","year":"2012","unstructured":"Baumgart S, Glesel E, Singh G, Chen NM, Reutlinger K, Zhang J, et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology. 2012;142(2):388-398.e1-7.","journal-title":"Gastroenterology"},{"issue":"1","key":"18186_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12867-017-0097-9","volume":"18","author":"M Malsy","year":"2017","unstructured":"Malsy M, Graf B, Almstedt K. Interaction between NFATc2 and the transcription factor Sp1 in pancreatic carcinoma cells PaTu 8988t. BMC Mol Biol. 2017;18(1):20.","journal-title":"BMC Mol Biol"},{"issue":"1","key":"18186_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12858-019-0105-4","volume":"20","author":"M Malsy","year":"2019","unstructured":"Malsy M, Graf B, Almstedt K. The active role of the transcription factor Sp1 in NFATc2-mediated gene regulation in pancreatic cancer. BMC Biochem. 2019;20(1):2.","journal-title":"BMC Biochem"},{"issue":"7","key":"18186_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/ncb816","volume":"4","author":"S Jauliac","year":"2002","unstructured":"Jauliac S, L\u00f3pez-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol. 2002;4(7):540\u20134.","journal-title":"Nat Cell Biol"},{"issue":"40","key":"18186_CR23","doi-asserted-by":"publisher","first-page":"16282","DOI":"10.1073\/pnas.1202989109","volume":"109","author":"X Ma","year":"2012","unstructured":"Ma X, Cai Y, He D, Zou C, Zhang P, Lo CY, et al. Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells. Proc Natl Acad Sci USA. 2012;109(40):16282\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"18186_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejrad.2017.03.021","volume":"91","author":"PL Zhou","year":"2017","unstructured":"Zhou PL, Wu G, Han XW, Bi YH, Zhang WG, Wu ZY. Detection and characterization of Budd-Chiari syndrome with inferior vena cava obstruction: comparison of fixed and flexible delayed scan time of computed tomography venography. Eur J Radiol. 2017;91:52\u20136.","journal-title":"Eur J Radiol"},{"issue":"3","key":"18186_CR25","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1053\/j.gastro.2009.10.045","volume":"138","author":"A K\u00f6enig","year":"2010","unstructured":"K\u00f6enig A, Linhart T, Schlengemann K, Reutlinger K, Wegele J, Adler G, et al. NFAT-induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology. 2010;138(3):1189-1199.e1-2.","journal-title":"Gastroenterology"},{"issue":"7579","key":"18186_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472\u20136.","journal-title":"Nature"},{"issue":"7579","key":"18186_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 2015;527(7579):525\u201330.","journal-title":"Nature"},{"issue":"12","key":"18186_CR28","doi-asserted-by":"publisher","first-page":"e1005251","DOI":"10.1371\/journal.pcbi.1005251","volume":"12","author":"R Gould","year":"2016","unstructured":"Gould R, Bassen DM, Chakrabarti A, Varner JD, Butcher J. Population Heterogeneity in the epithelial to mesenchymal transition is controlled by NFAT and phosphorylated Sp1. PLoS Comput Biol. 2016;12(12):e1005251.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"18186_CR29","doi-asserted-by":"publisher","first-page":"12355","DOI":"10.1038\/s41598-023-39626-0","volume":"13","author":"S Takahashi","year":"2023","unstructured":"Takahashi S, Takada I, Hashimoto K, Yokoyama A, Nakagawa T, Makishima M, et al. ESS2 controls prostate cancer progression through recruitment of chromodomain helicase DNA binding protein 1. Sci Rep. 2023;13(1):12355.","journal-title":"Sci Rep"},{"issue":"12","key":"18186_CR30","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2005-03-1167","volume":"106","author":"LV Pham","year":"2005","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood. 2005;106(12):3940\u20137.","journal-title":"Blood"},{"key":"18186_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.omtn.2020.05.016","volume":"20","author":"P Li","year":"2020","unstructured":"Li P, Zhang X, Wang L, Du L, Yang Y, Liu T, et al. lncRNA HOTAIR contributes to 5FU resistance through suppressing miR-218 and activating NF-\u03baB\/TS signaling in colorectal cancer. Mol Ther Nucleic Acids. 2020;20:879\u201380.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"18186_CR32","doi-asserted-by":"publisher","first-page":"101702","DOI":"10.1016\/j.gendis.2025.101702","volume":"12","author":"Y Wu","year":"2025","unstructured":"Wu Y, An G, Tong J, Zhang W, Tian Z, Dong B, et al. Galectin-3 in tumor-stromal cells enhances gemcitabine resistance in pancreatic adenocarcinoma by suppressing oxidative phosphorylation. Genes Dis. 2025;12(5):101702.","journal-title":"Genes Dis"},{"key":"18186_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jep.2019.02.029","volume":"235","author":"G Wang","year":"2019","unstructured":"Wang G, Wang YZ, Yu Y, Wang JJ. Inhibitory ASIC2-mediated calcineurin\/NFAT against colorectal cancer by triterpenoids extracted from Rhus chinensis Mill. J Ethnopharmacol. 2019;235:255\u201367.","journal-title":"J Ethnopharmacol"},{"issue":"10","key":"18186_CR34","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/bjc.2017.89","volume":"116","author":"S Han","year":"2017","unstructured":"Han S, Meng L, Jiang Y, Cheng W, Tie X, Xia J, et al. Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1\/FasL signalling. Br J Cancer. 2017;116(10):1302\u201311.","journal-title":"Br J Cancer"},{"issue":"1","key":"18186_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-022-02253-0","volume":"41","author":"W Liu","year":"2022","unstructured":"Liu W, Ren D, Xiong W, Jin X, Zhu L. A novel FBW7\/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression. J Exp Clin Cancer Res. 2022;41(1):38.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"18186_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/1759-7714.13038","volume":"10","author":"X Meng","year":"2019","unstructured":"Meng X, Li Z, Zhou S, Xiao S, Yu P. miR-194 suppresses high glucose-induced non-small cell lung cancer cell progression by targeting NFAT5. Thorac Cancer. 2019;10(5):1051\u20139.","journal-title":"Thorac Cancer"},{"issue":"23","key":"18186_CR37","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1091\/mbc.E15-07-0512","volume":"28","author":"H Moriya","year":"2017","unstructured":"Moriya H. Quantitative nature of overexpression experiments. Mol Biol Cell. 2017;28(23):3932\u20139. https:\/\/doi.org\/10.1091\/mbc.E15-07-0512.","journal-title":"Mol Biol Cell"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18186-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18186-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18186-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:18:18Z","timestamp":1762352298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18186-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["18186"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18186-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by the JSPS Grants-in-Aid for Scientific Research grant nos. 23K08183 to Y.H., Grant-in-Aid for Research Activity Start-up grant nos. 22K20841 to W.K., and Grant-in-Aid for Early-Career Scientists grant nos. 23K14609 to W.K. Makoto Ueno received honoraria from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, Yakult Honsha Co., Ltd., MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, J-pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K.; Research Funding from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K, MSD K.K, Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, Eisai Co., Ltd., Novartis Pharma K.K, Astellas Pharma Inc., J-pharma Co., Ltd., DFP (Delta Fly Pharma), Inc., Amgen Inc., and Chiome Bioscience Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}